PBS updates

Tibsovo (Ivosidenib)

ivosidenib 250 mg tablet, 60 · ORAL · PBS code 14868M

STREAMLINED

What it costs

AU$19920 PBS-determined price per 60 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2025-07-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Locally advanced or metastatic cholangiocarcinoma


Patient must have a test of tumour tissue confirming the presence of an IDH1 R132 variant; AND

Patient must have had systemic therapy for this condition prior to initiating treatment with this drug for this condition; AND

Patient must have/have had a WHO performance status of 2 or less at treatment initiation with this drug; AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

Confirm that evidence of the presence of a pathogenic variant of the IDH1 gene is documented/retained in the patient's medical records once only with the first PBS prescription.

Sponsor: Servier Laboratories (Aust.) Pty. Ltd. ABN 54 004 838 500

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.